AstraZeneca and Bristol Myers Squibb in $400 Billion Merger Talks
UK-based AstraZeneca and US-based Bristol Myers Squibb are reportedly in talks for a potential $400 billion merger, which would create one of the world's largest pharmaceutical companies. The deal, discussed over several months, raises questions about AstraZeneca's commitment to the UK as CEO Pascal Soriot pivots toward America. AstraZeneca shares fell 7% on the news. Both companies declined to comment, and the deal may not materialize.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection
Cross-source coverage
Wire timeline
AstraZeneca Shares Rebound After Reuters Report Dismisses Merger Speculation with Bristol Myers Squibb
AstraZeneca (AZN) shares rose about 6% on Wednesday after Reuters reported, citing a senior source, that there are no discussions between AstraZeneca and Bristol Myers Squibb (BMY) regarding a potential merger. This contradicted weekend speculation that had caused AstraZeneca's largest one-day share drop since 2020 on Monday. The combined company would have been valued near $400 billion. Analysts and investors had widely questioned the deal's strategic logic, with Jefferies calling it a 'head scratcher' and Union Investment saying it 'does not make strategic or financial sense.' Regulatory hurdles were also flagged due to overlapping cancer immunotherapy portfolios. AstraZeneca continues to report strong standalone results, including Q2 2026 EPS of $2.63 above consensus, and targets $80 billion annual revenue by 2030.
Senior Source Denies AstraZeneca-Bristol Myers Squibb Deal Talks
A senior source close to the matter told Reuters on Wednesday that there are 'no discussions' between AstraZeneca and Bristol Myers Squibb regarding a potential merger, quashing speculation of a nearly $400 billion deal. The source stated there never was a deal to be done and no active talks. Both companies declined to comment. The denial follows a Financial Times report on Sunday that the two drugmakers had held preliminary talks, which caused AstraZeneca shares to drop 9%. Following the Reuters denial, AstraZeneca shares rose 2.9% while Bristol Myers shares fell 2.6%. Another person familiar with the matter noted that given the deal's size, UK market abuse rules would have required an announcement if negotiations were underway.
Exclusive: No discussions over AstraZeneca-Bristol Myers deal, senior source says
A senior source close to the matter told Reuters on Wednesday that there are 'no discussions' ongoing between AstraZeneca and Bristol Myers Squibb regarding a potential merger, quashing speculation of a nearly $400 billion pharmaceutical deal. The source stated there never was a deal to be done and no talks are active. Both companies declined to comment. The denial follows a Financial Times report on Sunday that triggered a 9% drop in AstraZeneca shares. After Reuters' exclusive report, AstraZeneca shares rose 2.9%, while Bristol Myers shares fell 2.6%. Another person familiar with the matter noted that British market abuse rules would have required an announcement if negotiations were underway, given the deal's size.
Show 16 older updatesHide older updates
AstraZeneca and Bristol Myers Squibb Deny Merger Talks
A senior source close to the matter told Reuters on August 5, 2026, that AstraZeneca and Bristol Myers Squibb never held merger discussions and are not in talks now. The denial follows reports that the two pharmaceutical companies had been in preliminary discussions about a combination that could have created a company worth nearly $400 billion. AstraZeneca shares dropped roughly 9% following the initial deal reports, while Bristol Myers Squibb shares saw little movement. Analysts at Jefferies and Citi questioned the strategic rationale, noting significant overlap in oncology that would have drawn antitrust scrutiny. AstraZeneca's oncology franchise generated around $25 billion last year, while cancer drugs accounted for over 40% of Bristol Myers Squibb's sales in the first half of 2026. Bristol Myers Squibb faces pressure as exclusivity periods for key drugs like Opdivo and Eliquis wind down.
AstraZeneca and Bristol Myers Squibb Deny Merger Talks
A senior source close to the matter told Reuters on August 5, 2026, that AstraZeneca and Bristol Myers Squibb never held merger discussions and are not in talks now. The denial followed reports that the two pharmaceutical companies had been in preliminary discussions about a combination that could have created a company worth nearly $400 billion. AstraZeneca shares dropped roughly 9% following the initial deal reports, while Bristol Myers Squibb shares rose 6%. Analysts at Jefferies and Citi questioned the strategic rationale, noting significant overlap in oncology that would have drawn antitrust scrutiny. AstraZeneca's oncology franchise generated around $25 billion last year, while Bristol Myers Squibb faces pressure as exclusivity periods on key drugs like Opdivo and Eliquis wind down.
Bristol Myers Squibb Stock Falls on Report of $400 Billion Merger Talks With AstraZeneca
Bristol Myers Squibb (BMY) stock fell following a report that the company is in merger talks with AstraZeneca (AZN) in a potential deal valued at $400 billion. The report, published by Barron's on August 4, 2026, indicates that Wall Street is increasingly viewing the potential tie-up as unfavorable. Despite the decline, Bristol Myers Squibb stock had been up 21% for the year through the prior Friday's close. The article suggests investor skepticism about the mega-merger's benefits.
AstraZeneca shares slump after $400bn BMS merger rumours
Shares in AstraZeneca fell nearly 3% at market open on August 3, 2026, following a Financial Times report that the UK drugmaker is in talks with US-based Bristol Myers Squibb (BMS) about a potential mega-merger. The combined entity would be valued at nearly $400bn, making it one of the largest pharmaceutical companies globally and one of the biggest M&A deals in pharma history. The deal structure is unclear but would likely involve cash and shares. Citi analysts expressed surprise given AstraZeneca's strong pipeline and 2030 revenue targets, though they noted complementary portfolios. The talks follow AstraZeneca's NYSE listing in February 2026 and CEO Pascal Soriot's consideration of delisting from the LSE. The merger would face US antitrust scrutiny and must align with President Trump's domestic manufacturing agenda. The article notes that mega-mergers between major drugmakers have been rare since the early 2000s.
AstraZeneca shares slump after $400bn BMS merger rumours
Shares in AstraZeneca fell nearly 3% on August 3, 2026, following a Financial Times report that the UK drugmaker is in merger talks with US rival Bristol Myers Squibb (BMS). A potential deal would create one of the world's largest pharmaceutical companies with a combined value of nearly $400bn, ranking among the largest in pharma M&A history. The structure is unknown but would involve cash and shares. Citi analysts expressed surprise given AstraZeneca's strong pipeline and momentum. The talks come after AstraZeneca listed on the NYSE in February 2026, and a deal could heighten concerns about the UK pharma industry's competitiveness. Any tie-up would need to align with US President Trump's domestic manufacturing agenda and pass antitrust evaluations.
Bristol Myers Squibb Stock Jumps on Reported Merger Talks With AstraZeneca
Bristol Myers Squibb (BMY) shares surged over 4% in premarket trading on Monday following a report from The Financial Times that the company held merger talks with AstraZeneca (AZN). The potential mega-merger could create a combined drugmaker valued at nearly $400 billion. However, the report noted that the talks might be abandoned due to concerns about political pushback and the close competitive nature of several of their drugs, including cancer treatments. AstraZeneca's U.S.-listed shares fell 6% on the news. AstraZeneca declined to comment, while Bristol Myers Squibb did not immediately respond. Such a deal would give AstraZeneca greater access to the U.S. market, where it recently completed a direct listing on the NYSE and plans to invest $50 billion by 2030. Through Friday's close, AstraZeneca shares were down 3% for 2026, while Bristol Myers Squibb shares had gained over 20%.
AstraZeneca and Bristol Myers Squibb in Talks for $400 Billion Merger
British pharmaceutical giant AstraZeneca and US rival Bristol Myers Squibb have held discussions about a potential merger valued at nearly $400 billion, according to a Financial Times report. The deal would create one of the world's largest pharmaceutical groups and bolster AstraZeneca's presence in the United States. AstraZeneca, valued at £196 billion ($264 billion) before the report, saw its share price drop over 7% in early London trading. BMS is worth $133 billion. The talks, which have occurred in recent months, could yield a deal soon but may also be delayed or collapse. Both companies reported strong quarterly profits driven by cancer drug sales. AstraZeneca aims for the US market to account for half its global revenue by 2030 and recently listed shares on the NYSE.
AstraZeneca and Bristol Myers Squibb in Talks for $400 Billion Merger
British pharmaceutical giant AstraZeneca has held discussions with US rival Bristol Myers Squibb (BMS) about a potential merger valued at nearly $400 billion, according to a Financial Times report. If completed, the deal would create one of the world's largest pharmaceutical groups and strengthen AstraZeneca's presence in the US market. AstraZeneca's share price fell over 7% in early London trading following the report. The companies have held talks in recent months, but the deal could still be delayed or fall apart. AstraZeneca, valued at £196 billion ($264 billion) before the report, and BMS, worth $133 billion, both reported strong quarterly profits driven by cancer drug sales. AstraZeneca aims for the US market to account for half its global revenue by 2030 and recently began listing shares on the NYSE.
AstraZeneca and Bristol Myers Squibb Reportedly in Early Merger Talks
AstraZeneca and Bristol Myers Squibb are reportedly in early-stage merger talks, according to a Financial Times report. The potential deal could create a combined company worth nearly $400 billion, making it one of the largest pharmaceutical mergers in history. AstraZeneca's stock fell up to 7% on the news, while Bristol Myers Squibb shares rose 6% in premarket trading. Analysts expressed surprise and skepticism, given AstraZeneca's strong growth and innovation pipeline. The merger would face significant antitrust scrutiny due to overlapping oncology portfolios, with both companies deriving over 40% of revenue from cancer drugs. Bristol Myers Squibb is under pressure as patents for key drugs like Opdivo and Eliquis expire by 2028. AstraZeneca has declined to comment, and Bristol Myers Squibb has not responded to inquiries. The talks may not result in any agreement.
AstraZeneca share price tumbles as investors doubt merger with US rival
AstraZeneca's share price fell 6% in early trading after reports emerged that the UK drugmaker is exploring a potential $400bn merger with US rival Bristol Myers Squibb. Investors reacted negatively, signaling opposition to the deal, which would be one of the largest in history. Analysts cited concerns over the company's pivot toward the US, potential antitrust scrutiny due to overlapping oncology portfolios, and the risk of losing AstraZeneca's status as a FTSE 100 crown jewel. The deal also raises fears of further damage to the London stock exchange, which has seen a wave of takeovers. Despite the company's assurances it will remain based in Cambridge and retain its London listing, the market remains skeptical.
AstraZeneca shares drop 7% after report on $400 billion merger talks with Bristol Myers Squibb
AstraZeneca shares fell as much as 7% following a Financial Times report that the UK drugmaker is in talks with US peer Bristol Myers Squibb over a potential merger that could value the combined company at roughly $400 billion. The companies have discussed the deal over several months, though sources cautioned it may not come together. AstraZeneca, with a market cap of $264 billion, has seen steady growth under CEO Pascal Soriot and targets $80 billion in sales by 2030. Bristol Myers has a market cap of about $133 billion. Analysts at Jefferies expressed surprise at the news, noting AstraZeneca's strong growth and innovation profile and questioning the need for financial engineering. Both companies declined or did not immediately respond to requests for comment.
AstraZeneca explores $400bn megamerger with US rival Bristol Myers Squibb
AstraZeneca, the UK's second most valuable listed company, is exploring a $400bn (£300bn) merger with US rival Bristol Myers Squibb, which would create one of the world's largest pharmaceutical groups. The FTSE 100 giant has held talks with the US group in recent months about a possible tie-up, according to the Financial Times. Any potential transaction would likely consist of a combination of cash and shares. AstraZeneca has a market valuation of £196bn, while Bristol Myers Squibb is worth roughly $133bn. The deal has raised questions over AstraZeneca's ties to the UK, as CEO Sir Pascal Soriot pushes a pivot towards North America, having previously described the company as 'very American'. Last September, AstraZeneca upgraded its New York stock exchange listing, and struck a $50bn deal with the Trump administration to invest in US manufacturing. The company insists it will remain based in Cambridge and retain its London listing.
AstraZeneca held talks with Bristol Myers Squibb on US$400 billion megadeal: source
According to a source cited by The Business Times, AstraZeneca has held talks with Bristol Myers Squibb regarding a potential merger valued at US$400 billion. If completed, the deal would create one of the world's largest pharmaceutical companies. The report notes that this potential deal comes about a dozen years after AstraZeneca successfully fended off a takeover attempt by rival Pfizer. The article is based on a single unnamed source and was published on August 3, 2026.
AstraZeneca plots £300bn tie-up with US rival Bristol Myers Squibb
AstraZeneca, Britain's second-most valuable company, is reportedly in talks with US pharmaceutical giant Bristol Myers Squibb about a potential $400bn (£300bn) merger, which would be one of the largest in history. AstraZeneca is valued at around £196bn on the London Stock Exchange, while Bristol Myers Squibb is worth roughly $133bn. The deal would create one of the world's largest pharmaceutical companies but raises fresh questions about AstraZeneca's commitment to the UK, as CEO Sir Pascal Soriot has been increasingly pivoting towards America. Last year, AstraZeneca upgraded its New York listing and struck a $50bn deal with the Trump administration for US manufacturing. The proposed merger recalls Pfizer's failed attempt to take over AstraZeneca a decade ago, which collapsed due to political and board resistance. AstraZeneca currently employs about 10,000 staff in the UK.
AstraZeneca shares plunge on reports of $400bn merger talks with Bristol Myers Squibb
AstraZeneca shares dropped 9% on Monday, wiping £18bn off its market value, after reports emerged that the British pharmaceutical giant held talks about a potential $400bn (£300bn) mega-merger with US rival Bristol Myers Squibb. If completed, the deal would create one of the world's largest drugmakers but faces significant hurdles. Analysts expressed skepticism, calling the merger high-risk and questioning its strategic logic. Jefferies analysts said AstraZeneca does not need financial engineering, while Union Investment's portfolio manager Markus Manns stated the combination 'does not make strategic or financial sense.' The deal would also likely face intense scrutiny from US competition regulators and the Trump administration, given both companies' large cancer treatment portfolios. The news raises further concerns about AstraZeneca's ties to Britain, as CEO Pascal Soriot has previously described the company as 'very American' and recently upgraded its New York listing. AstraZeneca has insisted it intends to remain headquartered in Cambridge and retain its London listing.
AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports
According to a Financial Times report, UK pharmaceutical giant AstraZeneca is considering a merger with US rival Bristol Myers Squibb, which would create a combined company valued at approximately $400 billion. The deal, if finalized, would be one of the largest in history. Sources told the FT that the companies have been discussing the merger over the last few months, though it remains unclear whether the deal will come together. Both AstraZeneca and Bristol Myers Squibb did not immediately respond to CNBC's request for comment. The report highlights Bristol Myers Squibb's acquisition strategy, including its purchase of Medarex, which added a key melanoma drug in Phase III trials with potential applications for lung and prostate cancer.